Table 1.

Demographic and clinical characteristics

	N=36
Age, mean (SD)	49.5 (12.2)
Sex, n (%)
Female	19 (52.8)
Male	17 (47.2)
BMI, mean (SD)	30.0 (8.5)
Smoking history, n (%)
Current	16 (44.4)
Ex-smoker	8 (22.2)
Non-smoker	12 (33.3)
Psoriasis type, n (%)
Plaque	32 (88.9)
Nail involvement	5 (13.9)
Scalp involvement	9 (25.0)
Pustular	4 (11.1)
Inversa	3 (8.3)
Duration of skin disease, years, mean (SD)	16.7 (16.8)
Duration of arthralgia, months, mean (SD)	3.8 (3.4)
Inflammatory arthralgia	34 (94.6%)
Non-specific arthralgia	2 (5.6%)
Family history (1st grade), n (%)
Psoriasis	12 (33.3)
Rheumatic disease	3 (8.3)
Physical activity
Sport
Sedentary lifestyle	20 (55.5%)
1 hour or less weekly	5 (13.9%)
1–3.5 hours weekly	5 (13.9%)
3.5–7 hours weekly	4 (11.1%)
More than 7 hours weekly	2 (5.6%)
Occupational
Sedentary work	21 (58.3%)
Some physical activity	6 (16.7%)
Physically demanding work	9 (25.0%)
Disease activity
C reactive protein, mg/dL, mean (SD)	6.1 (1.9)
Pain VAS, mm, mean (SD)	43 (22)
Tender joint count 68, median (IQR)	1 (0–5)
Swollen joint count 66, median (IQR)	0 (0–0)
LEI, median (IQR)	0.0 (0.0–1.3)
MASES, median (IQR)	0.0 (0.0–1.5)
HAQ, median (IQR)	0.1 (0.0–0.6)
Treatment
Topical therapies, n (%)	25 (69.4)
Oral glucocorticoids, n (%)	0 (0)
NSAIDs (occasional use), n (%)	17 (47.2)
csDMARDs, n (%)	0 (0)
bDMARDs, n (%)	7 (19.5)
Ustekinumab	4 (11.1)
Guselkumab	1 (2.8)
Risankizumab	1 (2.8)
Ixekizumab	1 (2.8)

bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; LEI, Leeds Enthesitis Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; NSAIDs, non-steroidal anti-inflammatory drugs; VAS, Visual Analogue Scale.